Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Captor Therapeutics SA logo — Captor Therapeutics aims to treat cancer, infections, and di...

Captor Therapeutics SA

Captor Therapeutics aims to treat cancer, infections, and diseases by targeting the difficult-to-drug proteome.

Founded 2017 Poland Poland 79 employees IPO Total: $68.50M Biopharma, Biotechnology +1

General Information

Company Name Captor Therapeutics SA
Founded Year 2017
Location Poland Poland +1
Employees 79
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage IPO
Social

Get notified when Captor Therapeutics SA moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Captor Therapeutics recently secured significant post-IPO equity funding, indicating sustained investor confidence in its drug development pipeline. This capital infusion is well-timed with the crucial advancement of their lead project, Viadrudomide, into Phase I clinical trials for solid tumors. Furthermore, the company is actively showcasing its scientific progress, presenting new data on its MCL-1 degrader program at key industry congresses, highlighting ongoing R&D momentum.

Signal Types
Funding Product Development Regulatory Milestone Scientific Visibility
Strategic Labels
Clinical Advancement Pipeline Development Post-IPO Growth
Next Move: Trials
·
Impact: 8/10
·
Ideal For: Biotech Growth Investors — Clinical Stage

About Captor Therapeutics SA

Captor Therapeutics SA is a pioneering company in the Biopharma, Biotechnology, and Pharmaceutical industries, headquartered in Poland. Founded in 2017, the company is publicly listed on the Warsaw Stock Exchange under the ticker WSE:CTX.

Captor Therapeutics focuses on advancing drug discovery and development through targeted protein degradation to address the "undruggable" proteome. Its mission is to significantly impact the lives of patients suffering from cancer, autoimmunity, and neurodegenerative diseases by developing innovative therapeutics. The company prides itself on groundbreaking technology capable of producing new drug candidates aimed at curing conditions traditionally challenging to treat.

Recently, Captor Therapeutics secured a substantial PLN66.00M Post IPO Equity investment on 01 March 2026, with participation from the EIC Fund, underscoring investor confidence in its potential to transform patient outcomes and address critical medical challenges.

Taxonomy: Targeted Protein Degradation, Drug Discovery, Cancer Treatment, Autoimmune Disease Treatment, Neurodegenerative Disease Treatment, Proteome Targeting, Biotechnology Innovation, Pharmaceutical Development, Undruggable Proteome, Pharmacokinetics and Pharmacodynamics, Intracellular Protein Degradation, Small Molecule Therapeutics, European Union Co-financed Projects

Services & Products

Drug discovery using Targeted Protein Degradation (TPD) technology
Development of therapeutics for cancer and autoimmune diseases
Structure-guided optimization of lead compounds

Target Customers

Healthcare providers Pharmaceutical companies Patients with severe conditions like cancer and autoimmune diseases Research institutions

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity •••••• 1 •••• •••• 01 Mar 2026
Early VC •••••• 1
Investor
01 Oct 2024
IPO •••••• - 01 Apr 2021

Captor Therapeutics SA Alternatives & Competitors

Captor Therapeutics SA vs
AnHorn Medicines
AnHorn Medicines Taiwan

Innovation to New Therapeutics - New Opportunities to Target Difficult-to-treat Diseases

12 employees
Health and Wellness
Compare Captor Therapeutics SA vs AnHorn Medicines
Captor Therapeutics SA vs
Nurix Therapeutics
Nurix Therapeutics United States

Nurix is writing medicine’s next chapter using targeted protein degradation as a new script to outma...

IPO
370 employees
Biotechnology
Compare Captor Therapeutics SA vs Nurix Therapeutics
Captor Therapeutics SA vs
TRIANA Biomedicines
TRIANA Biomedicines

A venture-backed biopharmaceutical company dedicated to discovering and developing novel therapeutic...

Also compare with: Captor Therapeutics SA vs Amphista Therapeutics Limited Amphista Therapeutics Limited

FAQ About Captor Therapeutics SA

Captor Therapeutics aims to treat cancer, infections, and diseases by targeting the difficult-to-drug proteome.
Captor Therapeutics SA was founded in 2017.
Captor Therapeutics SA is headquartered in Poland.
Captor Therapeutics SA operates in the following industries: Biopharma, Biotechnology, Pharmaceutical.
Captor Therapeutics SA has approximately 79 employees.
Captor Therapeutics SA has completed 3 funding rounds, raising a total of $68.50M. The latest funding stage is IPO.
Captor Therapeutics SA offers: Drug discovery using Targeted Protein Degradation (TPD) technology, Development of therapeutics for cancer and autoimmune diseases, Structure-guided optimization of lead compounds.
Top alternatives and competitors to Captor Therapeutics SA include AnHorn Medicines, Nurix Therapeutics, TRIANA Biomedicines, Amphista Therapeutics Limited, C4 Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Captor Therapeutics SA and AnHorn Medicines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Captor Therapeutics SA and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy